Protalix BioTherapeutics (PLX) Announces Enrollment of First Patient in OPRX-106 Phase 2
Tweet Send to a Friend
Protalix BioTherapeutics, Inc. (NYSE: PLX) announced that the first patient has been enrolled in its phase II clinical trial of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE